VICL (Vical Labs) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	5/7/2009 4:01:11 PM
	of 1972

Vical and U.S. Navy to Expedite Development of H1N1 Pandemic Influenza (Swine Flu) Vaccine SAN DIEGO, May 6, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (NasdaqGM:VICL - News) announced today that the company has entered into a Cooperative Research and Development Agreement (CRADA(i)) with the U.S. Naval Medical Research Center (NMRC), a biomedical research organization within the U.S. Navy, for the expedited development of a vaccine against the potentially pandemic H1N1 strain of influenza virus. The goal of the collaborative development program is to rapidly advance a Vaxfectin(r)-formulated H1N1 DNA vaccine into clinical testing as quickly as possible. Vical would be responsible for securing regulatory approval of the vaccine for use in the United States and other countries. ``The rapid spread and potential impact of H1N1 influenza have led to a U.S. government declaration of a health care emergency and a World Health Organization (WHO) declaration of a Phase 5 pandemic alert,'' said Vijay B. Samant, Vical's President and Chief Executive Officer. ``We believe our technology is particularly well-suited to emerging infectious diseases like H1N1 influenza for which conventional vaccine technologies are too slow in both development and manufacturing. The successful completion of Phase 1 human trials of our Vaxfectin(r)-formulated DNA vaccines against H5N1 pandemic influenza last year positions us to pursue rapid development of a vaccine to address the threat of an influenza pandemic. We are pleased to collaborate with the U.S. Navy on this H1N1 vaccine development mission.'' About Vical Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at vical.com.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next